RPG LIFE SCIENCES
|
RPG LIFE SCIENCES Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 69.64 | 110.80 | 53.01 | 40.90 | 31.13 |
| CEPS(Rs) | 82.63 | 123.76 | 63.33 | 50.27 | 40.60 |
| DPS(Rs) | 24.00 | 24.00 | 16.00 | 12.00 | 9.60 |
| Book NAV/Share(Rs) | 366.06 | 320.80 | 226.67 | 186.00 | 154.66 |
| Tax Rate(%) | 25.31 | 21.32 | 25.61 | 26.22 | 29.64 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.57 | 22.69 | 20.70 | 18.66 | 18.18 |
| EBIT Margin(%) | 20.62 | 33.46 | 19.12 | 16.73 | 15.55 |
| Pre Tax Margin(%) | 20.38 | 33.24 | 18.89 | 16.53 | 15.26 |
| PAT Margin (%) | 15.22 | 26.15 | 14.05 | 12.19 | 10.74 |
| Cash Profit Margin (%) | 18.06 | 29.21 | 16.79 | 14.99 | 14.00 |
| Performance Ratios | |||||
| ROA(%) | 15.89 | 31.35 | 18.82 | 17.71 | 15.89 |
| ROE(%) | 20.28 | 40.48 | 25.69 | 24.01 | 21.80 |
| ROCE(%) | 26.99 | 51.79 | 34.96 | 32.92 | 31.46 |
| Asset Turnover(x) | 1.04 | 1.20 | 1.34 | 1.45 | 1.48 |
| Sales/Fixed Asset(x) | 2.53 | 2.82 | 2.83 | 2.73 | 2.61 |
| Working Capital/Sales(x) | 2.08 | 2.03 | 3.73 | 3.44 | 3.78 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.39 | 0.36 | 0.35 | 0.37 | 0.38 |
| Receivable days | 49.08 | 35.40 | 25.32 | 23.17 | 34.41 |
| Inventory Days | 52.31 | 50.53 | 57.35 | 58.57 | 53.79 |
| Payable days | 138.19 | 139.59 | 147.58 | 128.38 | 132.94 |
| Valuation Parameters | |||||
| PER(x) | 26.57 | 20.56 | 28.87 | 17.01 | 17.98 |
| PCE(x) | 22.39 | 18.40 | 24.16 | 13.84 | 13.78 |
| Price/Book(x) | 5.05 | 7.10 | 6.75 | 3.74 | 3.62 |
| Yield(%) | 1.30 | 1.05 | 1.05 | 1.72 | 1.72 |
| EV/Net Sales(x) | 4.13 | 5.55 | 4.29 | 2.13 | 1.94 |
| EV/Core EBITDA(x) | 16.84 | 20.93 | 18.29 | 10.10 | 9.48 |
| EV/EBIT(x) | 18.74 | 15.47 | 20.91 | 11.78 | 11.48 |
| EV/CE(x) | 4.67 | 6.84 | 6.65 | 3.56 | 2.48 |
| M Cap / Sales | 4.32 | 5.76 | 4.35 | 2.24 | 2.10 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 8.28 | 12.26 | 13.50 | 16.51 | 13.11 |
| Core EBITDA Growth(%) | 0.14 | 27.10 | 25.87 | 20.05 | 25.61 |
| EBIT Growth(%) | -33.48 | 96.57 | 28.49 | 24.47 | 34.69 |
| PAT Growth(%) | -37.15 | 109.03 | 29.60 | 31.39 | 28.70 |
| EPS Growth(%) | -37.15 | 109.03 | 29.60 | 31.39 | 28.70 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.03 | - | - | - | - |
| Current Ratio(x) | 3.27 | 3.88 | 2.28 | 2.57 | 2.58 |
| Quick Ratio(x) | 2.50 | 3.11 | 1.50 | 1.64 | 1.55 |
| Interest Cover(x) | 88.12 | 147.47 | 82.83 | 80.72 | 52.89 |
| Total Debt/Mcap(x) | 0.01 | - | - | - | - |
Compare Financial Ratios of peers of RPG LIFE SCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| RPG LIFE SCIENCES | ₹4,244.5 Cr | -6.7% | -16.8% | 27.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,662.0 Cr | 2% | -4.4% | 3.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹257,903.0 Cr | 7.1% | 2.5% | 46.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹176,306.0 Cr | 1.4% | -5.7% | 27.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,699.0 Cr | 3.6% | 8% | 4.2% | Stock Analytics | |
| CIPLA | ₹111,489.0 Cr | 2% | -0.2% | -14.3% | Stock Analytics | |
RPG LIFE SCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| RPG LIFE SCIENCES | -6.7% |
-16.8% |
27.1% |
| SENSEX | 1.8% |
2.3% |
-11.9% |
You may also like the below Video Courses
